June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Family History of Age-related Macular Degeneration (AMD) and Genetic Variants Predict Progression to Advanced AMD, Adjusting for Baseline Macular Status, Demographic and Lifestyle Predictors
Author Affiliations & Notes
  • Johanna M Seddon
    Department of Ophthalmology and Visual Sciences, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
  • Dikha De
    Department of Ophthalmology and Visual Sciences, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
  • Bernard Rosner
    Channing Division of Network Medicine, Harvard Medical School, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Johanna Seddon Apellis Pharmaceuticals, Code I (Personal Financial Interest), Gemini Therapeutics, Code O (Owner); Dikha De None; Bernard Rosner None
  • Footnotes
    Support  NIH R01-EY011309; R01-EY028602; R01-EY022445; American Macular Degeneration Foundation, Northampton, MA and Macular Degeneration Center of Excellence, University of Massachusetts Chan Medical School, Department of Ophthalmology and Visual Sciences, Worcester, MA
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2768. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Johanna M Seddon, Dikha De, Bernard Rosner; Family History of Age-related Macular Degeneration (AMD) and Genetic Variants Predict Progression to Advanced AMD, Adjusting for Baseline Macular Status, Demographic and Lifestyle Predictors. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2768.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine if family history of age-related macular degeneration (AMD) and genetic variants identify eyes at higher risk for progression to advanced AMD (AAMD), after controlling for baseline demographics, behavioral factors, and macular status.

Methods : Eyes with non-advanced AMD at baseline in the AREDS longitudinal cohort were classified using the AREDS severity score. Non-genetic and genetic predictors for progression to AAMD were evaluated. Cox proportional hazards models based on the eye as the unit of analysis were used to calculate hazard ratios (HR), accounting for correlated data. A composite risk score was calculated using beta estimates from demographic and behavioral variables (age, race, BMI, smoking status, AREDS treatment group, multivitamin intake), ocular factors (baseline AMD severity group and AMD status of fellow eye), AMD family history, and 12 statistically significant genetic variants (complement, angiogenesis, lipid, inflammatory, extra-cellular matrix, and DNA repair pathways) were selected from stepwise regression. Discrimination between progressing and non-progressing eyes in various models with different predictors was assessed using C-statistics and Net Reclassification Improvement (NRI).

Results : Among 4910 eyes, 863 progressed to AAMD over 12 years. Baseline AMD severity group and status of the fellow eye were important predictors, and genetic factors provided additional discrimination. Family history of AMD also independently predicted progression after accounting for genetic and other covariates: 1 family member vs. none (HR = 1.21, 95% CI: 1.02, 1.43; P = 0.03); ≥ 2 family members vs. none (HR= 1.55, 95% CI: 1.26, 1.90; P < 0.001). The composite risk score predicted progression to AAMD (HR = 5.57, 90th vs. 10th percentile), providing superior fit versus other models with only ocular or non-genetic variables (NRI, P < 0.001). It also discriminated between progressing and non-progressing eyes within each baseline AMD severity group (see figure). An online risk calculator is available to implement these methods.

Conclusions : Genetic variants and family history provided additional discrimination in AAMD prediction models, after accounting for ocular and other covariates.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

Composite Risk Scores for progressing and non-progressing eyes

Composite Risk Scores for progressing and non-progressing eyes

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×